Brokerages Expect Assembly Biosciences Inc (ASMB) Will Announce Quarterly Sales of $3.21 Million

Wall Street brokerages expect Assembly Biosciences Inc (NASDAQ:ASMB) to post $3.21 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Assembly Biosciences’ earnings. The highest sales estimate is $3.22 million and the lowest is $3.20 million. Assembly Biosciences reported sales of $2.66 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 20.7%. The firm is scheduled to announce its next earnings report on Wednesday, November 7th.

According to Zacks, analysts expect that Assembly Biosciences will report full-year sales of $13.05 million for the current year, with estimates ranging from $12.00 million to $13.60 million. For the next financial year, analysts forecast that the company will report sales of $25.90 million, with estimates ranging from $12.87 million to $63.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Assembly Biosciences.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.42). Assembly Biosciences had a negative net margin of 457.20% and a negative return on equity of 66.34%. The business had revenue of $3.22 million for the quarter, compared to analysts’ expectations of $3.30 million.

A number of brokerages recently issued reports on ASMB. Zacks Investment Research raised shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a research report on Tuesday. B. Riley raised shares of Assembly Biosciences from a “neutral” rating to a “buy” rating and set a $42.00 price target for the company in a research report on Monday, October 8th. ValuEngine cut shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 3rd. Robert W. Baird began coverage on shares of Assembly Biosciences in a research report on Wednesday, August 8th. They set an “outperform” rating and a $74.00 price target for the company. Finally, BidaskClub cut shares of Assembly Biosciences from a “sell” rating to a “strong sell” rating in a research report on Friday, July 13th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $62.60.

In other Assembly Biosciences news, insider Uri A. Lopatin sold 15,540 shares of the firm’s stock in a transaction dated Thursday, September 6th. The shares were sold at an average price of $40.09, for a total transaction of $622,998.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Derek A. Small acquired 2,400 shares of Assembly Biosciences stock in a transaction on Thursday, July 19th. The shares were purchased at an average price of $41.48 per share, with a total value of $99,552.00. Following the completion of the purchase, the chief executive officer now owns 668,091 shares in the company, valued at approximately $27,712,414.68. The disclosure for this purchase can be found here. 18.20% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in ASMB. Bank of Montreal Can bought a new stake in Assembly Biosciences during the 2nd quarter valued at about $145,000. Quantbot Technologies LP bought a new stake in shares of Assembly Biosciences in the first quarter worth approximately $154,000. Jane Street Group LLC bought a new stake in shares of Assembly Biosciences in the first quarter worth approximately $204,000. MetLife Investment Advisors LLC bought a new stake in shares of Assembly Biosciences in the second quarter worth approximately $282,000. Finally, Quantitative Systematic Strategies LLC bought a new stake in shares of Assembly Biosciences in the second quarter worth approximately $348,000. Institutional investors and hedge funds own 65.21% of the company’s stock.

NASDAQ ASMB traded up $0.42 during trading hours on Wednesday, reaching $24.01. 215,867 shares of the company’s stock traded hands, compared to its average volume of 213,636. Assembly Biosciences has a 52-week low of $23.05 and a 52-week high of $67.36. The stock has a market cap of $945.08 million, a P/E ratio of -9.96 and a beta of 0.80.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.

Featured Article: How to Use the New Google Finance Tool

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply